Alzheimer's disease therapy monitoring with MRI
50 Million people suffer from Alzheimer’s disease (AD) worldwide. 1.6 Million people die from AD every year, making AD the second leading cause for death in Neurology worldwide.1
Until now it has no cure, but recently, drugs that can slow the progress of Mild Cognitive Impairment (MCI) – the early stage of Alzheimer’s Disease (AD) – have become available. Possible side effects of these drugs are called Amyloid Related Imaging Abnormalities (ARIA), and MRI is the method of choice to monitor these for the occurrence of ARIA.
In July 2023, the US Food and Drug Administration (FDA) for the first time gave traditional approval to amyloid beta directed antibody for the treatment of AD. With such Disease Modifying Therapies (DMTs) entering the clinic, the potential to improve patient care and possibly slow disease progression is enormous.